ArticleJournal of extracellular vesicles2022
Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.
Article in Journal of extracellular vesicles, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities.Human vaccines & immunotherapeutics · 2026Article
- Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Isolation, Characterization, and Anti-Inflammatory Effects ofFoods (Basel, Switzerland) · 2026Article
- Immune-modified exosome vaccine loaded with liver cancer epitope peptides induces potent and specific antitumor immunity.Journal of nanobiotechnology · 2026Article
- A Unique Chimeric RNA: ERCC1-iASPP Drives Benzo[a]pyrene-Induced Lung Carcinogenesis via Dual Coding and Non-Coding Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The role and prospects of extracellular vesicles in advanced drug and vaccine delivery.Frontiers in immunology · 2026Review
- The promising cancer treatment approach in cancer immunotherapy: dendritic cell-based vaccines.Frontiers in immunology · 2026Review
- The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.Frontiers in oncology · 2026Review
- Biomimetic nanoimmunotherapy boosts spatiotemporal PANoptosis and reshapes desmoplastic tumor microenvironment.Cell reports. Medicine · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer.ACS nano · 2025Review
- Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine.Journal of cancer research and clinical oncology · 2024Review
- OncogenicMedComm · 2024Article
- Review
- Roles of exosomes in immunotherapy for solid cancers.Cell death & disease · 2024Review
- SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model.iScience · 2024Article
- Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress.Cell death discovery · 2024Article
- Extracellular vesicle-mediated communication between CD8Frontiers in immunology · 2024Review
- Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.Molecular aspects of medicine · 2023Review
- Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer vaccines critically rely on the availability of targetable immunogenic cancer-specific neoepitopes. However, mutation-based immunogenic neoantigens are rare or even non-existent in subgroups of cancer types. To address this issue, we exploited a cancer-specific aberrant transcription-induced chimeric RNA, designated A-P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.